Redeye: SciBase - Germany shines and financing sorted
Redeye saw a Q1 report that was slightly weaker than expected but not a material deviation. The German market continues to develop well and is profitable. The US delayed Medicare fee schedule review affected sales negatively in the quarter, but this issue has now been resolved. We have made small adjustments to our estimates and left our fair value range and Base case unchanged. With the financing sorted, the focus is now on the company's performance in the coming quarter.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/